Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671570 | 1.00 | OPRL1 (0.43) | OPRL1CYP2D6PKMCYP2C19PTGDR2 | |
| SCHEMBL4611839 | 0.79 | DPP4 (0.41) | PKMGRM5 | |
| SCHEMBL4611836 | 0.79 | DPP4 (0.41) | PKMGRM5 | |
| SCHEMBL5671796 | 0.77 | OPRL1 (0.43) | OPRL1CYP2D6PKMCYP2C19PTGDR2 | |
| SCHEMBL5669532 | 0.77 | OPRL1 (0.42) | OPRL1CYP2D6PKMCYP2C19PTGDR2 | |
| SCHEMBL5671997 | 0.77 | CYP2D6 (0.45) | OPRL1CYP2D6PKMCYP2C19PTGDR2 | |
| SCHEMBL5669537 | 0.77 | OPRL1 (0.42) | OPRL1CYP2D6PKMCYP2C19PTGDR2 | |
| SCHEMBL5671999 | 0.77 | CYP2D6 (0.45) | OPRL1CYP2D6PKMCYP2C19PTGDR2 | |
| SCHEMBL5669798 | 0.76 | MMP3 (0.44) | CYP2C19ADAM10ALDH1A1 | |
| SCHEMBL5669934 | 0.72 | CNR1 (0.41) | OPRL1PTGDR2GRM5KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | OPRL1 1506/4885CYP2D6 2584/4885PKM 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.